rupiya.io
⠋Loading...
0%
❯ Reading balance sheets...
Cipla is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Cipla Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
Deep-dive analysis of Cipla's competitive moat, management quality, and growth runway available with Premium.
Premium| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹11,345 Cr | ₹13,790 Cr | ₹14,394 Cr | ||||||||
| Expenses | ₹9,183 Cr | ₹11,310 Cr | ₹11,898 Cr | ||||||||
| Operating Profit | ₹2,163 Cr | ₹2,480 Cr | ₹2,496 Cr | ||||||||
| OPM % | 19.0% | 18.0% | 17.0% | ||||||||
| Other Income | ₹164 Cr | ₹208 Cr | ₹208 Cr | ||||||||
| Depreciation | ₹505 Cr | ₹754 Cr | ₹1,323 Cr | ||||||||
| Interest | ₹168 Cr | ₹207 Cr | ₹159 Cr | ||||||||
| Profit Before Tax | ₹1,654 Cr | ₹1,727 Cr | ₹1,222 Cr | ||||||||
| Tax | ₹1,654 Cr | ₹1,727 Cr | ₹1,222 Cr | ||||||||
| Net Profit | ₹1,229 Cr | ₹1,383 Cr | ₹1,035 Cr | ||||||||
| EPS (₹) | 14.7 | 16.9 | 12.5 | ||||||||
| Dividend Payout % | 14% | 12% | 16% |
Register free to see 8 more years.
| Quarter | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹5,739 Cr | ₹6,329 Cr | ₹6,678 Cr | ₹6,604 Cr | ||||||||
| Expenses | ₹4,566 Cr | ₹4,835 Cr | ₹4,944 Cr | ₹4,856 Cr | ||||||||
| Operating Profit | ₹1,174 Cr | ₹1,494 Cr | ₹1,734 Cr | ₹1,748 Cr | ||||||||
| OPM % | 20.0% | 24.0% | 26.0% | 26.0% | ||||||||
| Depreciation | ₹346 Cr | ₹239 Cr | ₹290 Cr | ₹233 Cr | ||||||||
| Interest | ₹34 Cr | ₹16 Cr | ₹26 Cr | ₹30 Cr | ||||||||
| Net Profit | ₹522 Cr | ₹998 Cr | ₹1,155 Cr | ₹1,068 Cr | ||||||||
| EPS (₹) | 6.5 | 12.3 | 14.0 | 13.1 |
Register free to see 8 more quarters.
| Period | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹161 Cr | ₹161 Cr | ₹161 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹10,641 Cr | ₹11,356 Cr | ₹12,383 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹1,703 Cr | ₹5,202 Cr | ₹4,113 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹3,166 Cr | ₹4,331 Cr | ₹4,213 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹15,670 Cr | ₹21,049 Cr | ₹20,869 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹6,830 Cr | ₹9,368 Cr | ₹9,492 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹640 Cr | ₹759 Cr | ₹973 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹7,620 Cr | ₹8,862 Cr | ₹8,721 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹15,670 Cr | ₹21,049 Cr | ₹20,869 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 8 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2016 | ₹1,173 Cr | ₹-950 Cr | ₹165 Cr | — |
| Mar 2017 | ₹1,741 Cr | ₹-4,533 Cr | ₹3,104 Cr | — |
| Mar 2018 | ₹2,382 Cr | ₹-1,304 Cr | ₹-1,326 Cr | — |
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 8 more years.
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 14.5% | 14.8% | 14.1% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 16.0% | 16.3% | 15.7% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.5 | 0.5 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 12.6 | 6.2 | 5.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.5 | 1.8 | 1.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.1 | 1.2 | 1.2 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 13.9% | 15.0% | 14.3% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 8.4% | 9.0% | 8.6% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 17.1 | 15.7 | 17.3 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 2.0 | 1.8 | 2.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 1.4 | 1.5 | 0.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 11.1 | 9.0 | 8.1 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹6.24 |
| FY23 | Final | ₹7.74 |
| FY22 | Interim | ₹17.82 |
| FY21 | Interim | |
| FY20 | Interim | |
| FY19 | Final |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
| Torrent Pharmaceuticals Ltd | ₹1,49,446 Cr | 69.7 | 0.00% | +15.25% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.